Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kuros Reshuffles Execs Post-Cytos Merger

This article was originally published in Clinica

Executive Summary

Tissue repair and regeneration specialist Kuros Biosciences has reshuffled its senior management team following the merger with Cytos Biotechnology, completed on Jan 20. The combined company, which will take the Kuros name, is headed by Kuros Biosciences’ existing CEO Didier Cowling. Cytos’ former CEO Christian Itin is chairman of the board of directors, and vice-chair is Dominik Ellenrieder. The new Kuros’ senior executive team also includes: Alistair Irvine, chief business officer; Jason Schense, chief technology officer; and Harry Welten, chief financial officer. Zurich-based Kuros is trialing biomaterials for use in neuro- and spinal surgery. With the addition of Cytos, the combined company also has therapeutic candidates targeting the cancer and hepatitis B markets.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT103150

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel